David Einhorn - DME Capital Management
Holding/activity history for Gain Therapeutics, Inc. (GANX)
← All GANX superinvestors
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 566,130 | 0.03 | $1.94 | $1,098,292 | SEC | ||
| 2025 Q4 | 566,130 | 0.06 | $3.22 | $1,822,939 | SEC | ||
| 2025 Q3 | 566,130 | 0.04 | $1.77 | $1,002,050 | SEC | ||
| 2025 Q2 | 566,130 | 0.04 | $1.80 | $1,019,034 | SEC | ||
| 2025 Q1 | 566,130 | 0.05 | $1.91 | $1,081,308 | SEC | ||
| 2024 Q4 | 566,130 | 0.06 | $2.16 | $1,222,841 | SEC | ||
| 2024 Q3 | 566,130 | 0.04 | $1.78 | $1,007,711 | SEC | ||
| 2024 Q2 | 566,130 | 0.04 | $1.28 | $724,646 | SEC | ||
| 2024 Q1 | 566,130 | 0.10 | Reduce 3.79% | <0.01 | $3.17–5.33 · VW $4.34i | $2,134,310 | SEC |
| 2023 Q4 | 588,410 | 0.09 | $3.26 | $1,921,158 | SEC | ||
| 2023 Q3 | 588,410 | 0.11 | Add 7.66% | <0.01 | $3.03–4.78 · VW $3.80i | $1,929,985 | SEC |
| 2023 Q2 | 546,560 | 0.11 | $4.48 | $2,448,589 | SEC | ||
| 2023 Q1 | 546,560 | 0.14 | $4.82 | $2,634,419 | SEC | ||
| 2022 Q4 | 546,560 | 0.12 | $3.13 | $1,710,732 | SEC | ||
| 2022 Q3 | 546,560 | 0.13 | $3.26 | $1,781,000 | SEC | ||
| 2022 Q2 | 546,560 | 0.15 | $3.60 | $1,967,000 | SEC | ||
| 2022 Q1 | 546,560 | 0.14 | $4.09 | $2,236,000 | SEC | ||
| 2021 Q4 | 546,560 | 0.17 | $5.43 | $2,968,000 | SEC | ||
| 2021 Q3 | 546,560 | 0.27 | $7.44 | $4,069,000 | SEC | ||
| 2021 Q2 | 546,560 | 0.35 | $10.00 | $5,466,000 | SEC | ||
| 2021 Q1 | 546,560 | 0.58 | Buy | 0.58 | $11.30–15.50 · VW $13.13i IPO/listing quarter |
$8,155,000 | SEC |
Price snapshot:
Current price$1.76
Avg. buy price$14.09
+/- since buy-87.51%
52-week low$1.41
52-week high$4.34